ATEA PHARMACEUTICALS, INC.

(AVIR)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/19/2022 05/20/2022 05/23/2022 05/24/2022 05/25/2022 Date
7.25(c) 7.49(c) 7.3(c) 7.53(c) 7.34(c) Last
935 309 608 739 635 381 562 810 702 735 Volume
+1.54% +3.31% -2.54% +3.15% -2.52% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 - - -
Net income 2022 -183 M - -
Net cash position 2022 592 M - -
P/E ratio 2022 -3,34x
Yield 2022 -
Sales 2023 108 M - -
Net income 2023 -214 M - -
Net cash position 2023 743 M - -
P/E ratio 2023 -2,87x
Yield 2023 -
Capitalization 611 M 611 M -
EV / Sales 2022 -
EV / Sales 2023 -1,22x
Nbr of Employees 64
Free-Float 89,5%
More Financials
Company
Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing, and commercializing antiviral therapeutics to enhace the lives of patients suffering from life-threatening viral infections. The Company is engaged in the development of product candidates to treat COVID-19, hepatitis C virus (HCV), dengue and respiratory syncytial virus (RSV). The Company is... 
More about the company
Ratings of Atea Pharmaceuticals, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
C-
More Ratings
All news about ATEA PHARMACEUTICALS, INC.
05/10ATEA PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition..
AQ
05/10TRANSCRIPT : Atea Pharmaceuticals, Inc., Q1 2022 Earnings Call, May 10, 2022
CI
05/10Atea Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 3..
CI
05/10Atea Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business..
AQ
05/03Atea Pharmaceuticals to Host First Quarter 2022 Financial Results Conference Call on Ma..
AQ
03/294794 : Characterization of the Toxicity Profile of AT-527 (Bemnifosbuvir), a Novel Guanosi..
PU
03/294793 : Lack of Reproductive and Developmental Toxicity for AT-527 (Bemnifosbuvir), an Oral..
PU
03/28Atea Pharmaceuticals Reports Nonclinical Bemnifosbuvir (AT-527) Toxicology Data at Soci..
AQ
03/02JPMorgan Adjusts Price Target for Atea Pharmaceuticals to $8 From $10, Maintains Neutra..
MT
03/01SVB Leerink Adjusts Atea Pharmaceuticals' Price Target to $9 from $10, Keeps Market Per..
MT
02/28ATEA PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition..
AQ
02/28ATEA PHARMACEUTICALS : Reports Fourth Quarter and Full Year 2021 Financial Results and Pro..
PU
02/28Atea Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31..
CI
02/28TRANSCRIPT : Atea Pharmaceuticals, Inc., Q4 2021 Earnings Call, Feb 28, 2022
CI
02/28ATEA PHARMACEUTICALS : Fourth Quarter 2021 Financial Results Conference Call Presentation
PU
More news
News in other languages on ATEA PHARMACEUTICALS, INC.
05/10Atea Pharmaceuticals, Inc. annonce ses résultats pour le premier trimestre clos le 31 m..
02/28Atea Pharmaceuticals, Inc. publie ses résultats pour l'année complète se terminant le 3..
02/28Atea Pharmaceuticals, Inc. annonce ses résultats pour le quatrième trimestre clos le 31..
02/10Atea Pharmaceuticals, Inc. annonce des changements de direction
02/02Atea Pharmaceuticals, Inc. annonce la publication dans Nature Communications de données..
More news
Analyst Recommendations on ATEA PHARMACEUTICALS, INC.
More recommendations
Chart ATEA PHARMACEUTICALS, INC.
Duration : Period :
Atea Pharmaceuticals, Inc. Technical Analysis Chart | AVIR | US04683R1068 | MarketScreener
Technical analysis trends ATEA PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 4
Last Close Price 7,34 $
Average target price 10,25 $
Spread / Average Target 39,6%
EPS Revisions
Managers and Directors
Jean-Pierre Sommadossi Chairman, President & Chief Executive Officer
Andrea J. Corcoran Executive Vice President-Legal & Administration
Maria Arantxa Horga Executive Vice President-Clinical Sciences
Keith Pietropaolo Senior Vice President-Clinical Operations
Claudio Avila Senior Vice President-Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
ATEA PHARMACEUTICALS, INC.-17.90%611
GILEAD SCIENCES, INC.-10.47%81 543
REGENERON PHARMACEUTICALS, INC.9.40%74 440
VERTEX PHARMACEUTICALS23.33%69 269
WUXI APPTEC CO., LTD.-22.98%39 423
BIONTECH SE-40.00%37 588